You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 65 No. 7, July 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Radiologic Imaging
 •Immunologic Disorders
 •Multiple Sclerosis/ Demyelinating Disease
 •Neuro-ophthalmology
 •Ophthalmology
 •Retinal/ Chorioretinal Disorders
 •Alert me on articles by topic

Retinal Imaging by Laser Polarimetry and Optical Coherence Tomography Evidence of Axonal Degeneration in Multiple Sclerosis

Maulik S. Zaveri, MS; Amy Conger, COA; Amber Salter, MS; Teresa C. Frohman, BA; Steven L. Galetta, MD; Clyde E. Markowitz, MD; Dina A. Jacobs, MD; Gary R. Cutter, PhD; Gui-Shuang Ying, PhD; Maureen G. Maguire, PhD; Peter A. Calabresi, MD; Laura J. Balcer, MD, MSCE; Elliot M. Frohman, MD, PhD

Arch Neurol. 2008;65(7):924-928.

Background  Optical coherence tomography (OCT) and scanning laser polarimetry with variable corneal compensation (GDx) are similar yet provide information on different aspects of retinal nerve fiber layer (RNFL) structure (thickness values similar to histology for OCT vs birefringence of microtubules for GDx).

Objectives  To compare the ability of OCT and GDx to distinguish eyes of patients with multiple sclerosis (MS) from eyes of disease-free controls and thus identify RNFL abnormalities. We also sought to examine the capacity of these techniques to distinguish MS eyes from those without a history of optic neuritis and to correlate with visual function.

Design  Cross-sectional study.

Setting  Academic tertiary care MS center.

Participants  Eighty patients with MS (155 eyes) and 43 disease-free controls (85 eyes) underwent both OCT and GDx imaging using protocols that measure RNFL thickness.

Main Outcome Measures  Areas under the curve (AUC), adjusted for within-patient, intereye correlations, were used to compare the abilities of OCT and GDx temporal-superior-nasal-inferior-temporal average RNFL thicknesses to discriminate between MS and control eyes and to distinguish MS eyes with a history of optic neuritis. Visual function was evaluated using low-contrast letter acuity and high-contrast visual acuity.

Results  Average peripapillary RNFL thickness (360° around the optic disc) was reduced in patients with MS compared with controls for both methods. Age-adjusted AUC did not differ between OCT (0.80; 95% confidence interval [CI], 0.72-0.88) and GDx (0.78; 95% CI, 0.68-0.86; P = .38). Optical coherence tomography–measured RNFL thickness was somewhat better at distinguishing MS eyes with a history of optic neuritis from those without (OCT: AUC, 0.73; 95% CI, 0.64-0.82; GDx: AUC, 0.66; 95% CI, 0.57-0.66; P = .17). Linear correlations of RNFL thickness for OCT vs GDx were significant yet moderate (r = 0.67, P < .001); RNFL thickness measures correlated moderately and significantly with low-contrast acuity (OCT: r = 0.54, P < .001; GDx: r = 0.55, P < .001) and correlated less with high-contrast visual acuity (OCT: r = 0.44, P < .001; GDx: r = 0.32, P < .001).

Conclusions  Scanning laser polarimetry with variable corneal compensation measurements of RNFL thickness corroborates OCT evidence of visual pathway axonal loss in MS and provides new insight into structural aspects of axonal loss that relate to RNFL birefringence (microtubule integrity). These results support validity for RNFL thickness as a marker for axonal degeneration and support use of these techniques in clinical trials that examine neuroprotective and other disease-modifying therapies.


Author Affiliations: Departments of Neurology (Mr Zaveri, Drs Galetta, Markowitz, Jacobs, and Balcer), Ophthalmology (Drs Galetta, Ying, Maguire, and Balcer), Biostatistics (Drs Ying and Maguire), and Epidemiology (Dr Balcer), University of Pennsylvania School of Medicine, Philadelphia; Department of Neurology, University of Texas Southwestern Medical Center, Dallas (Mss Conger, Salter, and T. C. Frohman and Dr E. M. Frohman); Department of Biostatistics, University of Alabama, Birmingham (Dr Cutter); and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland (Dr Calabresi).


RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(7):871-872.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.